Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TYGRIS: TYSABRI Global Observational Program in Safety

Trial Profile

TYGRIS: TYSABRI Global Observational Program in Safety

Phase of Trial: Phase IV

Latest Information Update: 17 Sep 2016

At a glance

  • Drugs Natalizumab (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions
  • Acronyms TYGRIS
  • Sponsors Biogen
  • Most Recent Events

    • 08 Sep 2016 According to Biogen media release, data from this trial will be presented at the 32nd congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
    • 19 Jun 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 26 Apr 2015 Planned End Date changed from 1 Sep 2014 to 1 May 2015 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top